Redefining endpoints in Alzheimer’s and dementia trials

Why traditional cognitive endpoints are insufficient in Alzheimer’s clinical trials

Alzheimer’s disease remains one of the most complex and urgent challenges in clinical research. Affecting more than 60 million people globally, AD is a progressive neurodegenerative disorder that begins developing decades before any symptoms appear.

While therapeutic innovation is accelerating, demonstrating treatment efficacy and safety continues to challenge clinical trials. Alzheimer’s disease and dementia clinical research has long relied on established cognitive scales to evaluate treatment efficacy. While these tools remain important, they increasingly struggle to capture the nuanced, real-world progression of early‑stage disease. Subtle cognitive changes, variable symptom presentation, and the influence of comorbid conditions often fall outside the scope of traditional, clinic‑based assessments.

At the same time, expectations for conducting dementia trials are rising. Sponsors, regulators, and clinicians are moving beyond a narrow definition of success toward a more holistic understanding of patient health, one that reflects both clinical benefit and safety in everyday life.

This shift demands a new approach to endpoint strategy that integrates cognitive performance, physiological safety, clinician observation, patient or caregiver-reported experience, and biological markers of disease progression.

Key challenges in Alzheimer’s disease clinical trial design and endpoint measurement

Alzheimer’s disease isn’t just a condition. It’s a spectrum of biological and clinical changes that unfold over time and may present differently for those affected.

• Neurovascular changes begin 15–20 years before clinical symptoms emerge
• Disease progression varies widely across patients
• Cognitive, behavioral, and functional decline do not always align
• Traditional endpoints often lack sensitivity to detect subtle changes

These realities create significant hurdles in demonstrating efficacy, maintaining consistency in endpoints and ratings, and ensuring the right participants are recruited. To meet these challenges, clinical trials increasingly rely on multi-modal, objective, and sensitive measures to capture disease progression.

How imaging biomarkers measure disease progression in dementia trials

Neuroimaging has evolved from a diagnostic checkpoint to a powerful longitudinal outcome measure in dementia research. Within the context of the drug development space, imaging biomarkers may be used for myriad purposes including patient selection during enrollment, safety monitoring, or finding out if a therapy is having the desired effect.

Advanced MRI and PET imaging enable researchers to quantify structural and molecular changes that provide objective evidence of disease pathology. Examples of imaging biomarkers include shifts in amyloid or tau burden, hippocampal atrophy, and cortical thinning. These insights are especially critical in early‑stage trials, where cognitive changes may be modest but biological effects are already underway. To date, amyloid clearance is the sole surrogate biomarker accepted by the FDA for accelerated approval of AD drugs.

Imaging also plays an essential role in safety oversight, particularly in immunotherapy studies where monitoring for Amyloid‑Related Imaging Abnormalities (ARIA) is mandatory.

With integrated imaging acquisition, centralized reads, and analytics expertise, Clario helps sponsors align imaging endpoints with cognitive and functional outcomes that connect biological change to clinical relevance.

Gait and mobility as digital biomarkers in neuroscience clinical trials

Cognitive decline in Alzheimer’s disease does not occur in isolation; it is increasingly understood as part of a broader disruption across interconnected brain systems. Growing evidence shows that gait, balance, and overall mobility are closely linked to neurological function, with shared neural pathways connecting motor control and cognitive processing. Subtle changes in how a person walks, such as reduced gait speed, increased variability, or impaired balance, falls can emerge early and may even predict future cognitive decline or progression to dementia.

For clinical trials, this connection presents an important opportunity. Instrumented gait and mobility assessments provide objective, quantifiable endpoints that go beyond traditional cognitive testing. Using precise digital tools, researchers can capture nuanced movement patterns with a level of sensitivity that reflects underlying neurological change. These measures also complement cognitive assessments by offering a more holistic view of how disease progression impacts real-world function.

How eCOA captures patient‑reported outcomes in dementia clinical trials

Dementia lives outside the clinic. Historically, trial assessments utilized paper clinical outcome assessments which often rely on recall‑based or site‑administered tools that fail to reflect daily functioning.

(Read more about eCOA vs. paper-based clinical outcome assessments and when it’s recommended to use eCOA here.)

Electronic Clinical Outcome Assessments (eCOAs) and eDiaries offer a better outlook into the patient experience. By capturing input directly from patients and caregivers in real time, these tools illuminate how disease and treatment affect activities of daily living (ADLs) that include managing medications to preparing meals or navigating familiar environments.

This shift places emphasis on quality of function, not just quantity of cognitive change. Electronic outcome assessments not only reduce common sources of reporting bias, recall error, and white coat effect but also improve compliance and data completeness.

eCOA solutions are designed to integrate seamlessly with other trial data streams, ensuring that the patient’s voice is not siloed, but contextualized alongside clinical, physiological, and imaging signals.

Why cardiac safety monitoring is essential in dementia clinical trials

Cognitive outcomes alone do not tell the full story in dementia trials. Most patients with dementia enter studies with preexisting cardiovascular conditions as the risk factors for both conditions overlap significantly. In addition, some investigational compounds carry known or emerging cardiac risk profiles, including effects on QT intervals, heart rate, or autonomic function.

Without robust cardiac safety monitoring early safety signals may go undetected.

The industry is increasingly moving beyond episodic, site‑based ECG assessments toward more standardized and, where appropriate, longitudinal cardiac monitoring strategies. Consistent ECG data collection and centralized review help distinguish treatment effects from confounding disease-related cardiovascular events, improving confidence in both safety and efficacy conclusions.

Deep expertise in cardiac safety enables dementia trials to account for heart‑brain interactions with the same rigor applied to cognitive outcomes to ensure patient safety while strengthening the interpretability of trial data.

What are composite endpoints in Alzheimer’s clinical trials and why they matter

A therapy that improves cognitive test scores but introduces cardiovascular risks, mobility issues, or reduced independence cannot be considered a clear success. True efficacy is defined by balanced benefit across domains.

Composite and global endpoints that draw from cognition, eCOA, imaging, and safety data enable a more complete assessment of treatment impact. These frameworks reduce reliance on any single measure and increase sensitivity to detect meaningful change, particularly in heterogeneous patient populations.

Regulatory agencies are increasingly supportive of this approach, recognizing that multi‑domain endpoints better reflect patient benefit and risk. Clario’s integrated data science and clinical expertise support the development and execution of these strategies, ensuring endpoints are both scientifically robust and operationally feasible.

The future of digital biomarkers and multimodal endpoints in neuroscience trials

The evolution of endpoint strategy in dementia trials represents more than a technical advancement. It signals a fundamental shift toward better science and better patient care.

By embracing digital‑first, multimodal approaches, sponsors can design studies that are more sensitive to change, more protective of patient safety, and more aligned with real‑world outcomes. Integrated endpoints improve confidence in decision‑making, help differentiate truly disease‑modifying therapies, and reduce the risk of late‑stage trial failure.

Redefining outcomes is central to advancing neuroscience research. By uniting cognitive, cardiac, imaging, and patient‑reported data within a single, cohesive framework, we help sponsors see the full picture – accelerating the path toward treatments that meaningfully improve the lives of people living with dementia.